[PDF][PDF] Phase I/II study of ipilimumab for patients with metastatic melanoma
JS Weber, S O'Day, W Urba, J Powderly… - Journal of Clinical …, 2008 - researchgate.net
JS Weber, S O'Day, W Urba, J Powderly, G Nichol, M Yellin, J Snively, E Hersh
Journal of Clinical Oncology, 2008•researchgate.netPurpose The primary objective of this phase I/II study was to determine the safety and
pharmacokinetic profile of either transfectoma-or a hybridoma-derived ipilimumab.
Secondary objectives included determination of a maximum-tolerated dose and assessment
of clinical activity.
pharmacokinetic profile of either transfectoma-or a hybridoma-derived ipilimumab.
Secondary objectives included determination of a maximum-tolerated dose and assessment
of clinical activity.
Purpose
The primary objective of this phase I/II study was to determine the safety and pharmacokinetic profile of either transfectoma-or a hybridoma-derived ipilimumab. Secondary objectives included determination of a maximum-tolerated dose and assessment of clinical activity.
researchgate.net